Fen-phen fallout: Back to basics?

Physician and Sportsmedicine

Volumn 26, Issue 1, 1998, Pages

  Potera, Carol ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMFEPRAMONE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; FLUOXETINE; HERBACEOUS AGENT; MAZINDOL; PHENDIMETRAZINE TARTRATE; PHENTERMINE; SERTRALINE; SIBUTRAMINE;

CARDIOTOXICITY; DRUG MECHANISM; EOSINOPHILIA MYALGIA SYNDROME; HUMAN; HYPERICUM PERFORATUM; NOTE; OBESITY; PRACTICE GUIDELINE; WEIGHT REDUCTION;

EID: 2642702580     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.1998.01.1570     Document Type: Note

References (6)

1. Mark EJ, Patalas ED, Chang HT, et al: Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997;337(9):602-606
2. Abenhaim L, Monde Y, Brenot F, et al: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335(9): 609-616
3. Connolly HM, Crary JL, McGoon MD, et al: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581-585
4. Graham DJ, Green L: Further cases of valvular heart disease associated with fenfluramine-phentermine, letter. N Engl J Med 1997;337(9):635
5. Centers for Disease Control and Prevention: Cardiac valvulopathy associ ated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR 1997;46(45):1061-1066
6. Anchors M: Safer Than Phen-fen. Rocklin, CA, Prima Publishing, 1997